Pesquisar
INmune Bio Inc
INMBAdicionar à lista de desejos
1.750USD
-0.020-1.13%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
46.52MValor de mercado
PerdaP/L TTM
Mais detalhes de INmune Bio Inc Empresa
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Informações de INmune Bio Inc
Código da empresaINMB
Nome da EmpresaINmune Bio Inc
Data de listagemFeb 04, 2019
CEOMoss (David J)
Número de funcionários22
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 04
Endereço225 Ne Mizner Blvd, Suite 640
CidadeBOCA RATON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33432
Telefone18589643720
Sitehttps://www.inmunebio.com/
Código da empresaINMB
Data de listagemFeb 04, 2019
CEOMoss (David J)
Executivos da empresa INmune Bio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
86.40K
+17.13%
Mr. David J. Moss
Mr. David J. Moss
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. J. Kelly Ganjei
Mr. J. Kelly Ganjei
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Mr. Cory Ellspermann
Mr. Cory Ellspermann
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
86.40K
+17.13%
Mr. David J. Moss
Mr. David J. Moss
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. J. Kelly Ganjei
Mr. J. Kelly Ganjei
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de INmune Bio Inc?
Os cinco principais acionistas de INmune Bio Inc são: Mr. Scott Juda, J.D.
Quantas instituições possuem ações da INmune Bio Inc (INMB)?
Em 2026Q1, 186 instituições possuíam ações da INmune Bio Inc, com valor de mercado aproximado de 5.01M, representando 18.84% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2542427.00.